Navigation Links
Indevus and FDA Agree on Path Forward for NEBIDO(R)
Date:9/26/2008

l trials prior to resubmission or approval," stated Glenn L. Cooper, M.D., chairman and chief executive officer of Indevus. "FDA also agreed with our outline of the proposed risk mitigation plans that included appropriate labeling description of intramuscular injection technique, adequate labeling information regarding allergic and oil-based reactions, and the commitment to conduct a large, simple post-marketing study. Risk mitigation plans are now commonly added to approval of new drugs and our agreed plans are consistent with FDA's new initiatives for the management of safety of new drugs. Given a six month FDA review time, assuming approval, we will be in a position to launch NEBIDO with our sales force in the fourth quarter of calendar 2009. We remain enthusiastic about the marketplace opportunity for a long-acting injectable testosterone therapy and we expect the introduction of NEBIDO to have a significant positive impact on the Company's business plan."

About NEBIDO(R)

NEBIDO(R) is a long-acting depot preparation of testosterone undecanoate under development for the treatment of male hypogonadism. NEBIDO is expected to be the first long-acting testosterone preparation available in the U.S. in the growing market for testosterone replacement therapies. Indevus acquired U.S. rights to NEBIDO from Bayer Schering Pharma AG, Germany in July 2005.

About Indevus

Indevus Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in the acquisition, development, and commercialization of products to treat conditions in urology and endocrinology. The Company's approved products include SANCTURA(R) and SANCTURA XR(TM) for overactive bladder, VANTAS(R) for advanced prostate cancer, SUPPRELIN(R) LA for central precocious puberty, and DELATESTRYL(R) to treat male hypogonadism. The Indevus development pipeline contains multiple compounds within the Company's core therapeutic areas in addition to several partnered or partnerable programs. T
'/>"/>

SOURCE Indevus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Indevus Announces Private Placement of $105 Million of Non-Recourse Notes
2. Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM)
3. Indevus Pharmaceuticals to Announce Third Quarter Fiscal 2008 Financial Results on August 5, 2008
4. Indevus Receives Approvable Letter from FDA for NEBIDO(R)
5. Indevus Announces Management Changes
6. Indevus Pharmaceuticals Scheduled to Present at Upcoming Investor Conferences
7. 125 Indevus Sales Representatives to Provide Community Service in New Orleans for Jericho Road Episcopal Housing Initiative
8. Indevus Pharmaceuticals to Present at Cowen and Company 28th Annual Health Care Conference
9. Indevus Comments on Bayer Healthcare Discontinuation of Viadur(R)
10. Indevus Receives Non-Approvable Letter From FDA for VALSTAR(TM)
11. Indevus Pharmaceuticals Announces Retirement of David B. Sharrock From Its Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... 28, 2014  Next month, executives from clinical trial marketing ... events beginning with Patient-Centered Clinical Trials 2014 , to ... Boston , September 4-5. Patient recruitment experts Bonnie ... Fleishman will share insights on the benefits of employing ... tactics – from media to mobile apps – can be ...
(Date:8/28/2014)... Aug. 28, 2014  Armetheon, Inc. ( www.armetheon.com ... mid- to late-stage cardiovascular drug candidates, today announced ... first round of financing. The Series A round ... Bioventures with participation from investors that included Atheneos ... Dr. Larry Hsu , the founder of ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 A ... around the world is available from Strategic Consulting, ... companies. “ Industrial Microbiology Market Review, Fourth Edition: ... Market ” (IMMR—4) tracks and compares microbiology test ... North America, Europe and Asia, and forecasts future ...
(Date:8/28/2014)... Supplementing their complete line of ... Eppendorf Safe Lock Centrifuge Tubes . This ... quality tubes at an affordable price. Eppendorf Safe ... chemical, medical, pharmaceutical, and life science research and ... able to afford Eppendorf products. , Eppendorf is ...
Breaking Biology Technology:BBK Worldwide Leads Sessions at Key September Events 2Armetheon Completes $7.0 Million Series A Financing 2Armetheon Completes $7.0 Million Series A Financing 32 Billion Industrial Microbiology Tests Conducted for Product Quality and Safety Worldwide 22 Billion Industrial Microbiology Tests Conducted for Product Quality and Safety Worldwide 3Eppendorf Safe Lock Centrifuge Tube Promotion Now Available at Major Pipette Distributor Pipette.com 2Eppendorf Safe Lock Centrifuge Tube Promotion Now Available at Major Pipette Distributor Pipette.com 3
... 1 A new technology known as,ActivePure ... proven in peer-reviewed, published university laboratory studies ... inoculated,surfaces. Recent outbreaks of MRSA in ... parents concerned. Based on NASA research, ...
... Nov. 1 Martek Biosciences,Corporation (Nasdaq: MATK ... United,States District Court in Wilmington, Delaware, has ruled ... injunction in Martek,s favor,against the defendants in the ... Nutrinova Inc. and Nutrinova Nutrition Specialties &,Food Ingredients ...
... ON, Nov. 1 /PRNewswire-FirstCall/ - Vasogen Inc.,(NASDAQ: VSGN ; ... following investor conferences in November: Acumen BioFin Rodman ... New York Palace Hotel Tuesday, November 6, 2007 ... Conference, Four Seasons Hotel, Boston Tuesday, November 13, ...
Cached Biology Technology:New ActivePure Technology Proven To Reduce Exposure to Methicillin Resistant Staphylococcus Aureus (MRSA) 2Martek to Obtain Permanent Injunction Against Lonza in U.S. Patent Infringement Suit; Jury Verdict on Infringement of Two of Three Patents Upheld by Judge 2Martek to Obtain Permanent Injunction Against Lonza in U.S. Patent Infringement Suit; Jury Verdict on Infringement of Two of Three Patents Upheld by Judge 3Vasogen to Webcast Presentations at Three Upcoming Healthcare Conferences 2Vasogen to Webcast Presentations at Three Upcoming Healthcare Conferences 3
(Date:8/27/2014)... is related to ability that we already possess. For ... more easily than learning how to hit a tennis ... Neural Basis of Cognition (CNBC)a joint program between the ... fundamental constraint in the brain that may explain why ... Aug. 28, 2014, issue of Nature , they ...
(Date:8/27/2014)... Athens, Ga. An invasive grass species frequently found ... spiders, who then feed on American toads, a new ... which was accidentally introduced to the U.S. in the ... species and has spread to more than a dozen ... Typically found along roads and in forests, it can ...
(Date:8/27/2014)... When we want to listen carefully to someone, the ... thing we do is stop moving altogether. This strategy ... by our own movements. , This interplay between movement ... brain. Indeed, indirect evidence has long suggested that the ... auditory cortex, which gives rise to our conscious perception ...
Breaking Biology News(10 mins):Pitt and Carnegie Mellon engineers discover why learning can be difficult 2Pitt and Carnegie Mellon engineers discover why learning can be difficult 3More wolf spiders feasting on American toads due to invasive grass, UGA study shows 2More wolf spiders feasting on American toads due to invasive grass, UGA study shows 3Stop and listen: Study shows how movement affects hearing 2Stop and listen: Study shows how movement affects hearing 3
... environmental enrichment and increased social stress can both affect ... monkey research at Wake Forest University School of Medicine., ... that social rank whether animals are dominant or ... amount of cocaine that monkeys will self-administer. Housed in ...
... Institute (HHMI) researchers have found that rare mutations in ... general population. , The scientists had previously shown that ... rare diseases that are characterized by low blood pressure. ... are participating in the Framingham Heart Study, the researchers ...
... Recent research at Yale provided a glimpse of ... illuminated a relationship between gene processing in humans and ... structure of a crucial self-splicing region of RNA. ... through intermediary RNA molecules. But, after transcription from the ...
Cached Biology News:Environmental enrichment can reduce cocaine use, researchers find 2Rare genetic mutations protect against hypertension 2Rare genetic mutations protect against hypertension 3Rare genetic mutations protect against hypertension 4Yale scientists visualize the machinery of mRNA splicing 2
{3,8-diamino-5-[3-(diethylmethylammonio)propyl]-6-phenylphenanthridinium diiodide}. ,250 ug/ml Propidium Iodide (PI) in PBS....
Propidium Iodide: {3,8-diamino-5-[3-(diethylmethylammonio)propyl]-6-phenylphenanthridinium diodide}. Antifade Solution: p-Phenylenediamine and glycerol in PBS solution. 2.5ug/mL Propidium Iodide (PI)...
Detects caspase activation by flow cytometry....
Concentration: 1mg/ml. Antigen: Propidium Iodide ...
Biology Products: